Globus Medical reported $745.342 million in sales and $76,109 million in operating margin for the quarter ending June 30, 2025. The second quarter beat expectations for revenue, profit margin, cash flow and EPS.
Globus Piles on Sales and Cash Flow Growth
3 min read Premium comments
Globus Medicalsecond quarter 2025 earningsKeith Pfeil
| Globus Medical, Inc. 2025 Report ($000s): 3 Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $629,691 | $745,342 | 18.37% | $1,236,357 | $1,343,463 | 8.66% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $49,622 | $76,109 | 53.38% | $57,619 | $173,113 | 200.44% | |
| 7.88% | 10.21% | 4.66% | 12.89% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $0.23 | $1.49 | 547.8% | $0.18 | $2.01 | 1016.7% | |
| 2026 Sales Estimate | 2025 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $2,860,000 | 6.29% | $2,680,000 | 57.80% | |||
Source: RRY Publications LLC
Keith Pfeil, Globus’s new president and chief executive officer and Kyle Klein, chief financial officer, broke the news about Q2’s solid beat in a recent call with analysts.
Globus Medical Piles It On: Sales, Profits, and Cash Flow Surge in Q2
When a company drops an 18% revenue jump and a 14% EPS boost, you know the Street will take notice. That’s exactly what Globus Medical delivered in Q2 2025, reporting $745 million in sales and $0.86 non-GAAP EPS per share — a solid beat that sent a clear message to competitors: Globus is doubling down.
A New Chapter, Same Playbook
On the analyst call, new president and CEO Keith Pfeil played the balancing act every fresh chief must: acknowledging the excitement of a new chapter while promising not to mess with the formula that got them here.
“I sit here today, excited for the opportunity and ready to begin a new chapter of the Globus story,” Pfeil said, before reminding analysts that the company’s mission and strategy remain unchanged: patient outcomes, unmet clinical needs, and relentless innovation.
And yes, he had plenty to say about the company’s merger and acquisition strategy, with NuVasive and Nevro now officially in the fold. Pfeil framed integration as fuel for the next stage: “Our team is intently focused on accelerating our product development engine to launch new and exciting products.”
Translation: Globus wants to keep its reps armed with the broadest bag in the business — and convert more competitor reps while they’re at it.
Enabling Tech: Robots in Focus
Naturally, analysts zeroed in on the robotics question. After a soft Q1, ExcelsiusGPS bounced back in Q2. Pfeil noted that most deals are still being done via outright purchase, but the company is leaning on flexible structures to meet customer needs.
And in case anyone wondered who Globus is gunning for, Pfeil left no doubt: “Our number one competitor is Medtronic. We go head-to-head with them, but we still think the superiority of our technology puts us ahead of the class.”
Nevro’s Role: Early but Promising
Matthew O’Brien from Piper Sandler pressed for clarity on Nevro’s sales trajectory. Was $65 million per quarter the right benchmark? CFO Kyle Klein stayed disciplined, offering only directional commentary, while Pfeil kept expectations in check: “It’s still too early to make broad-scale changes to our guidance, but we’re cautiously optimistic with where the Nevro business is.”
For now, Globus is holding to its $2.8–$2.9 billion revenue guidance for the year.
What It Means for Spine and Ortho Execs
Globus is signaling three big priorities to the market.
- Integration as acceleration – Folding in NuVasive and Nevro isn’t just consolidation; it’s about expanding the bag and keeping reps sticky.
- Robotics as a battleground – ExcelsiusGPS vs. Mazor is shaping up as the heavyweight fight of spine surgery enabling tech.
- Financial discipline – Growth is strong, but so is the emphasis on balance sheet strength and cash flow — a message designed to reassure investors amid M&A activity.
Of course, one CEO would take exception — the CEO who has captured more market share each year over the last five years than Globus or any other company — that would be Pat Miles and his team at Alphatec.
East vs West. Philly suburbs vs San Deigo suburbs. Two different philosophies. So far, the West Coast guys are winning the hearts and minds of Wall Street’s growth investors.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.